TABLE 1
FROM:
Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions
A Y L Ho, S Devereux, G J Mufti and A Pagliuca
BACK TO ARTICLETable 1. Patient characteristics at transplant
| Patient no. | Age/sex | Diagnosis to transplant(years) | IPI | ECOG | Diagnosis (stage) | Previous therapy |
|---|---|---|---|---|---|---|
| 1 | 55.8/m | 3.1 | 2 | 1 | Follicular NHL(IVB); local HG-transformation (Ia); 2nd PR | CHOP(5); RT; CHOP(6); mini-BEAM |
| 2 | 54.8/m | 3.0 | 2 | 1 | Follicular NHL (IVB); 1st PR | Chl/pred (8); FMD(4); CHOP(6); rituximab (1*) |
| 3 | 50.8/f | 1.5 | 2 | 1 | Follicular NHL (IVB); 1st PR | COP(3); FAD(6); rituximab(1*) |
| 4 | 50.9/f | 3.8 | 2 | 1 | Follicular NHL (IVB); 3rd PR | FAD(6); CMOP(3); rituximab(1*BEAM auto; rituximab(1*); DHAP(3); rituximab(1*) |
| 5 | 42.6/f | 3.2 | 2 | 1 | Composite follicular/mantle cell NHL (IIIA); 2nd CR | Intensified CHOP (HOVON26) (6); CVEP-rituximab(1*) |
CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone; mini-BEAM: BCNU 60 mg/m2 Day 1, etoposide 75 mg/m2 days 2–5, cytarabine 100 mg/m2 bd Days 2–5, melphalan 30 mg/m2 Day 6; chl/pred: chlorambucil/prednisolone; FMD: fludarabine, mitoxantrone, dexamethasone; COP: cyclophosphamide, vincristine, prednisolone; FAD: fludarabine, adriamycin, dexamethasone; CMOP: cyclophosphamide, mitoxantrone, vincristine, prednisolone; CVEP: cyclophosphamide, vincristine, etoposide, prednisolone; DHAP: dexamethasone, cisplatin, cytarabine; RT: radiotherapy; HOVON 26 intensified CHOP: cyclophosphamide 1000 mg/m2, doxorubicin 70 mg/m2, vincristine 2 mg, prednisolone 100 mg Days 1–5, G-CSF Days 2–11, 14-day cycle: 1* indicates one course of four weekly infusions of 375 mg/m2. PR: partial remission; CR: complete remission; IPI: International Prognostic Index; ECOG: Eastern Cooperative Oncology Group performance status.
